A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer

Launched by MBQ PHARMA · Oct 4, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new oral medication called MBQ-167 for patients with advanced breast cancer. It is specifically designed for individuals whose previous treatments have not worked or have caused intolerable side effects. The trial is currently recruiting participants who are at least 18 years old and have confirmed advanced breast cancer that has continued to progress despite other therapies. If you are considering joining, you should have a life expectancy of at least six months and be able to take capsules twice a day.

Participants in this study will receive MBQ-167, and doctors will monitor their health throughout the trial. It's important to note that individuals who cannot swallow capsules, are pregnant or breastfeeding, or have recently received other cancer treatments may not be eligible to participate. This trial is a chance to explore a new treatment option for advanced breast cancer, and your involvement could help advance medical knowledge in this area.

Gender

ALL

Eligibility criteria

• Key Inclusion Criteria:
• • The investigator will evaluate these and other criteria to determine whether a participant can be included in this study.
• • Histologically and/or cytologically confirmed advanced breast cancer which has progressed after treatment with approved therapies or for which there are no standard therapies available.
• • Participants with known brain metastases may be eligible if specific conditions are met.
• • Life expectancy ≥6 months, in the opinion of the investigator, after starting MBQ-167.
• • Are able to swallow capsules twice daily with a meal.
• Key Exclusion Criteria:
• • The investigator will evaluate these and other criteria to determine whether a participant should be excluded from this study.
• • Inability to take oral medication, or malabsorption syndrome or any other uncontrolled gastrointestinal condition (e.g., nausea, diarrhea, or vomiting) that might impair the bioavailability of MBQ-167.
• • Females who are pregnant or breastfeeding.
• • Participants who have received any anticancer treatment within 4 weeks or any investigational agent within 28 days prior to the first dose of trial drug or who have not recovered from any acute toxicity greater than Grade 0 or 1 related to previous anticancer treatment.
• • Participants who have received any anticancer treatment within 4 weeks or any investigational agent within 28 days prior to the first dose of trial drug or who have not recovered from any acute toxicity greater than Grade 0 or 1 related to previous anticancer treatment.
• • Active malignancies other than advanced breast cancer will be excluded from the study.